Christos Tsoukas

Summary

Affiliation: McGill University
Country: Canada

Publications

  1. pmc Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy
    Christos Tsoukas
    McGill University Health Centre, Montreal General Hospital, 1650 Cedar Ave, Rm A5 140, Montreal, QC H3G 1A4, Canada
    Blood 107:1785-90. 2006
  2. pmc Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries
    Janet M Raboud
    Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
    BMC Infect Dis 10:40. 2010
  3. pmc T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers
    Philomena Kamya
    Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
    AIDS Res Ther 8:20. 2011
  4. ncbi request reprint Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection
    Sabine Kinloch-de Loes
    Department of Medicine, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
    J Infect Dis 192:607-17. 2005
  5. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
  6. doi request reprint Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008

Collaborators

  • S P Curtis
  • Michael W Dunne
  • Jean Michel Molina
  • Edwin DeJesus
  • R M Gulick
  • Philomena Kamya
  • Pierre Cote
  • Janet M Raboud
  • Brian Conway
  • Benoit Trottier
  • Julio S G Montaner
  • Gerd Fatkenheuer
  • Manuel Battegay
  • David A Cooper
  • Pierre Marie Girard
  • Sabine Kinloch-de Loes
  • Salix Boulet
  • Rupert Kaul
  • Colin Kovacs
  • Nicole F Bernard
  • RéJean Thomas
  • Cecile L Tremblay
  • Mohamed Rachid Boulassel
  • Bernard Lessard
  • Mario Ostrowski
  • Jean Pierre Routy
  • Mark Tyndall
  • Nada Gataric
  • Svetlana Draskovic
  • Gloria Aykroyd
  • David Moore
  • Anya Shen
  • Irving Salit
  • DeSheng Su
  • Anita Rachlis
  • Roger Sandre
  • Marina B Klein
  • Sergio Rueda
  • Mona Loutfy
  • Benita Yip
  • Evelyne Ssengendo
  • Sean Rourke
  • Sherine Sterling
  • Joseph Cox
  • Shariq Haider
  • David Milan
  • Peggy Millson
  • Darien Taylor
  • Janet Raboud
  • Hong Yang
  • Nahimi Samia
  • Shari Margolese
  • Robert S Hogg
  • Marina Klein
  • George Hatzakis
  • Sharon Walmsley
  • Ahmed M Bayoumi
  • Zoran Stjepanovic
  • Curtis Cooper
  • Wendy Wobeser
  • Bruno Lemay
  • Mona R Loutfy
  • Maggie Li
  • Louise Balfour
  • Ed Mills
  • Sandra Gardner
  • David Haase
  • Marianne Harris
  • Marek Smieja
  • Sean Hosein
  • John Cairney
  • Richard Harrigan
  • Ahmed Bayoumi
  • Stanley Read
  • Liviana Calzavara
  • Silvia Guillemi
  • Mark Fisher
  • Danielle Rouleau
  • Jeff Cohen
  • Robert Hogg
  • Viviane Lima
  • P Richard Harrigan
  • Julio Montaner
  • Nima Machouf
  • Don Kilby
  • Richard Lalonde
  • Kevin Gough
  • Neora Pick
  • Jack Thomas Stapleton
  • Richard J Moore

Detail Information

Publications6

  1. pmc Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy
    Christos Tsoukas
    McGill University Health Centre, Montreal General Hospital, 1650 Cedar Ave, Rm A5 140, Montreal, QC H3G 1A4, Canada
    Blood 107:1785-90. 2006
    ..6%) and during part 2 between etoricoxib (77.0%) and rofecoxib (78.9%). We conclude that etoricoxib provided superior efficacy versus placebo for the treatment of hemophilic arthropathy and was generally safe and well tolerated...
  2. pmc Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries
    Janet M Raboud
    Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
    BMC Infect Dis 10:40. 2010
    ....
  3. pmc T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers
    Philomena Kamya
    Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
    AIDS Res Ther 8:20. 2011
    ..abstract:..
  4. ncbi request reprint Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection
    Sabine Kinloch-de Loes
    Department of Medicine, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
    J Infect Dis 192:607-17. 2005
    ..Our trial design appears to be feasible and safe for testing future immune-boosting strategies...
  5. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  6. doi request reprint Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....